Tracon Pharmaceuticals Sets Estimated IPO Range

San Diego-based biopharmaceuticals developer Tracon Pharmaceuticals said in a regulatory filing today that it is estimated its IPO pricing at between $12.00 and $14.00 per share. The company--which filed for an IPO over the holidays--is looking to raised $57.96M on the NASDAQ Global Market as TCON. Tracon's IPO is being underwritten by Wells Fargo Securities, Stifel, Needham & Company, and Oppenheimer & Co. The companyis venture backed by JAFCO Ventures, New Enterprise Associates, Brookline Investments, Nextech Oncology, BioMed Ventures, along with others. Tracon Pharmaceuticals is developing treatments for cancer, age-related macular degeneration (AMD) and fibrotic diseases.